Etanercept (Enbrel)

Etanercept (Enbrel) is a real, FDA-approved TNF-receptor-Fc fusion protein — one of the first biologic disease-modifying drugs for rheumatoid arthritis, approved in 1998, and now a textbook patent-thicket case study: FDA-approved US biosimilars have existed since 2016 without ever reaching a single American patient, blocked by patents that don't expire until 2029.

A TNF receptor spliced onto an antibody

Etanercept is a fusion protein: two copies of the extracellular, ligand-binding portion of the human TNF receptor (specifically the p75 receptor) genetically joined to the Fc fragment of human IgG1 — the same basic engineering logic behind romiplostim and aflibercept elsewhere on this site, applied here to soak up circulating tumor necrosis factor-alpha (TNF-α) before it can bind its natural receptors and drive inflammation. Developed by Immunex (acquired by Amgen in 2002), etanercept was among the first practical TNF blockers to reach the clinic and helped establish the entire TNF-inhibitor drug class that now also includes infliximab and adalimumab.

The approval and pivotal trial

The pivotal trial (Moreland LW, Baumgartner SW, Schiff MH, et al., "Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein," N Engl J Med 1997;337(3):141-147, PMID 9219699) was a 12-week, randomized, placebo-controlled, dose-ranging study in 180 patients with active, treatment-refractory rheumatoid arthritis: at the highest tested dose (16 mg/m², twice weekly), 75% of etanercept patients met the ACR20 response criterion (a composite 20% improvement across core disease measures) versus 14% on placebo — a large, clear effect that supported a fast track to approval. The FDA approved etanercept (as Enbrel) on 2 November 1998 for reducing the signs and symptoms of moderate-to-severe rheumatoid arthritis in adults who had not responded adequately to standard disease-modifying drugs. It has since gained additional approved indications, including juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis, each backed by its own dedicated trial program that we have not independently re-verified indication-by-indication here.

A three-decade patent thicket

Etanercept has become a widely cited case study in how a single biologic can be shielded from competition far longer than its original patent life would suggest. The FDA approved Sandoz's biosimilar, Erelzi (etanercept-szzs), on 30 August 2016 — the first etanercept biosimilar to clear FDA review — and a second, Eticovo (etanercept-ykro, Samsung Bioepis), on 25 April 2019. Neither has ever been sold in the US. Amgen (which inherited Enbrel through its 2002 acquisition of Immunex) asserted two later-acquired patents — originally developed by Roche and purchased by Amgen in 2011 — covering the etanercept molecule itself and its manufacturing process, with the later of the two not expiring until 2029, more than three decades after Enbrel's original 1998 approval. The Federal Circuit ruled against Sandoz's patent challenge in July 2020, and the US Supreme Court declined to hear a further appeal on 17 May 2021, leaving Erelzi (and Eticovo, blocked under a related settlement) locked out of the US market until April 2029 regardless of their FDA approval status.

Current status: declining sales, and a fresh antitrust fight

Enbrel remains FDA-approved and marketed by Amgen, but its US sales have fallen sharply through 2025 — reported quarterly sales down roughly 10-48% year-over-year across the year's four quarters — driven mainly by Medicare Part D redesign effects and pricing pressure, since no direct etanercept biosimilar has actually launched in the US to compete with it. That absence of competition is now itself being litigated: on 14 April 2025, Sandoz filed a US antitrust lawsuit against Amgen, alleging that Amgen's acquisition and use of the Roche-origin patents was itself an anticompetitive scheme to keep Erelzi off the market years longer than a legitimate patent term should allow, seeking damages plus an order permitting an earlier launch. As of this review, that case remains unresolved, and no etanercept biosimilar is sold in the US.